Darren DeStefano

Cooley advised Luna Innovations, a global leader in advanced fiber optic-based technology, on its $50 million investment from White Hat Capital Partners and its acquisition of Silixa.

Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised Thayer Ventures Acquisition Corp., a publicly traded special purpose acquisition company affiliated with Thayer Ventures, on its completed business combination with innovative luxury travel subscription brand Inspirato. Lawyers Daniel Peale, John McKenna, Milson Yu, Michelle Peleg, Shawn Fateh, Jonathan Camello, Brian Kloeblen and Angel Nwachukwu led the Cooley team advising Thayer Ventures.